RING finger ubiquitin protein ligases: Implications for tumorigenesis, metastasis and for molecular targets in cancer

Seminars in Cancer Biology

Volumn 13, Issue 1, 2003, Pages 5-14

  Fang, Shengyun ^a   Lorick, Kevin L ^a   Jensen, Jane P ^a   Weissman, Allan M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Autocrine motility factor receptor; BRCA1; E3; ERAD; Metastasis; Molecular target; Proteasome; RING finger; Ubiquitin; Ubiquitin protein ligase

Indexed keywords

AUTOCRINE MOTILITY FACTOR RECEPTOR; BRCA1 PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

CARCINOGENESIS; CELL FUNCTION; EUKARYOTIC CELL; METASTASIS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN MODIFICATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

EID: 0037331103     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(02)00095-0     Document Type: Article

References (123)

1. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67:1998;425-479.
2. Weissman A.M. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2:2001;169-178.
3. Hicke L. A new ticket for entry into budding vesicles-ubiquitin. Cell. 106:2001;527-530.
4. Ulrich H.D., Jentsch S. Two RING finger proteins mediate cooperation between ubiquitin-conjugating enzymes in DNA repair. EMBO J. 19:2000;3388-3397.
5. Roest H.P., van K.J., de W.J., van G.C.G., Koken M.H., Vermey M.et al. Inactivation of the HR6B ubiquitin-conjugating DNA repair enzyme in mice causes male sterility associated with chromatin modification. Cell. 86:1996;799-810.
6. Lohrum M.A., Woods D.B., Ludwig R.L., Balint E., Vousden K.H. C-terminal ubiquitination of p53 contributes to nuclear export. Mol. Cell Biol. 21:2001;8521-8532.
7. Deng L., Wang C., Spencer E., Yang L., Braun A., You J.et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 103:2000;351-361.
8. Salghetti S.E., Caudy A.A., Chenoweth J.G., Tansey W.P. Regulation of transcriptional activation domain function by ubiquitin. Science. 293:2001;1651-1653.
9. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70:2001;503-533.
10. Huibregtse J.M., Scheffner M., Beaudenon S., Howley P.M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl. Acad. Sci. U.S.A. 92:1995;2563-2567.
11. Scheffner M., Nuber U., Huibregtse J.M. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature. 373:1995;81-83.
12. Kumar S., Kao W.H., Howley P.M. Physical interaction between specific E2 and Hect E3 enzymes determines functional cooperativity. J. Biol. Chem. 272:1997;13548-13554.
13. Schwarz S.E., Rosa J.L., Scheffner M. Characterization of human HECT domain family members and their interaction with UbcH5 and UbcH7. J. Biol. Chem. 273:1998;12148-12154.
14. Lorick K.L., Jensen J.P., Fang S., Ong A.M., Hatakeyama S., Weissman A.M. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. U.S.A. 96:1999;11364-11369.
15. Lovering R., Hanson I.M., Borden K.L., Martin S., O'Reilly N.J., Evan G.I.et al. Identification and preliminary characterization of a protein motif related to the zinc finger. Proc. Natl. Acad. Sci. U.S.A. 90:1993;2112-2116.
16. Freemont P.S. The RING finger. A novel protein sequence motif related to the zinc finger. Ann. N. Y. Acad. Sci. 684:1993;174-192.
17. Freemont P.S. RING for destruction? Curr. Biol. 10:2000;R84-R87.
18. Joazeiro C.A., Weissman A.M. RING finger proteins: mediators of ubiquitin ligase activity. Cell. 102:2000;549-552.
19. Kamura T., Koepp D.M., Conrad M.N., Skowyra D., Moreland R.J., Iliopoulos O.et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science. 284:1999;657-661.
20. Skowyra D., Koepp D.M., Kamura T., Conrad M.N., Conaway R.C., Conaway J.W.et al. Reconstitution of G1 cyclin ubiquitination with complexes containing SCFGrr1 and Rbx1. Science. 284:1999;662-665.
21. Joazeiro C.A., Wing S.S., Huang H., Leverson J.D., Hunter T., Liu Y.C. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science. 286:1999;309-312.
22. Seol J.H., Feldman R.M., Zachariae W., Shevchenko A., Correll C.C., Lyapina S.et al. Cdc53/cullin and the essential Hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme Cdc34. Genes Dev. 13:1999;1614-1626.
23. Ohta T., Michel J.J., Schottelius A.J., Xiong Y. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol. Cell. 3:1999;535-541.
24. Tan P., Fuchs S.Y., Chen A., Wu K., Gomez C., Ronai Z.et al. Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of IκBα Mol. Cell. 3:1999;527-533.
25. Xie Y., Varshavsky A. The E2-E3 interaction in the N-end rule pathway: the RING-H2 finger of E3 is required for the synthesis of multiubiquitin chain. EMBO J. 18:1999;6832-6844.
26. Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275:2000;8945-8951.
27. Rasheed ZA, Saleem AM, Ravee Y, Rasheed FY, Liu LF, Rubin EH. The RING finger protein, topors, functions as an E3-type SUMO ligase for human DNA topoisomerase I. In: Proceedings of the 93rd Annual Meeting, vol. 43 (1156), 2002. p. 5730.
28. Aravind L., Koonin E.V. The U box is a modified RING finger - a common domain in ubiquitination. Curr. Biol. 10:2000;R132-R134.
29. Koegl M., Hoppe T., Schlenker S., Ulrich H.D., Mayer T.U., Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell. 96:1999;635-644.
30. Connell P., Ballinger C.A., Jiang J., Wu Y., Thompson L.J., Hohfeld J.et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 3:2001;93-96.
31. Meacham G.C., Patterson C., Zhang W., Younger J.M., Cyr D.M. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat. Cell Biol. 3:2001;100-105.
32. Jiang J., Ballinger C.A., Wu Y., Dai Q., Cyr D.M., Hohfeld J.et al. CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J. Biol. Chem. 276:2001;42938-42944.
33. Hatakeyama S., Yada M., Matsumoto M., Ishida N., Nakayama K.I. U-box proteins as a new family of ubiquitin-protein ligases. J. Biol. Chem. 276:2001;33111-33120.
34. Saha V., Chaplin T., Gregorini A., Ayton P., Young B.D. The leukemia-associated-protein (LAP) domain, a cysteine-rich motif is, present in a wide range of proteins, including MLL, AF10, and MLLT6 proteins. Proc. Natl. Acad. Sci. U.S.A. 92:1995;9737-9741.
35. Capili A.D., Schultz D.C., Rauscher F.J. III, Borden K.L. Solution structure of the PHD domain from the KAP-1 corepressor: structural determinants for PHD, RING and LIM zinc-binding domains. EMBO J. 20:2001;165-177.
36. Boname J.M., Stevenson P.G. MHC class I ubiquitination by a viral PHD/LAP finger protein. Immunity. 15:2001;627-636.
37. Coscoy L., Sanchez D.J., Ganem D. A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. J. Cell Biol. 155:2001;1265-1273.
38. Song Z., Krishna S., Thanos D., Strominger J.L., Ono S.J. A novel cysteine-rich sequence-specific DNA-binding protein interacts with the conserved X-box motif of the human major histocompatibility complex class II genes via a repeated Cys-His domain and functions as a transcriptional repressor. J. Exp. Med. 180:1994;1763-1774.
39. Misra S., Hurley J.H. Crystal structure of a phosphatidylinositol 3-phosphate-specific membrane-targeting motif, the FYVE domain of Vps27p. Cell. 97:1999;657-666.
40. Katzmann D.J., Babst M., Emr S.D. Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell. 106:2001;145-155.
41. Hochstrasser M. SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell. 107:2001;5-8.
42. Jackson P.K. A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev. 15:2001;3053-3058.
43. Kahyo T., Nishida T., Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol. Cell. 8:2001;713-718.
44. Kang E.S., Park C.W., Chung J.H. Dnmt3b, de novo DNA methyltransferase, interacts with SUMO-1 and Ubc9 through its N-terminal region and is subject to modification by SUMO-1. Biochem. Biophys. Res. Commun. 289:2001;862-868.
45. Sachdev S., Bruhn L., Sieber H., Pichler A., Melchior F., Grosschedl R. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev. 15:2001;3088-3103.
46. Schmidt D., Muller S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc. Natl. Acad. Sci. U.S.A. 99:2002;2872-2877.
47. Takahashi Y., Kahyo T., Toh-E A., Yasuda H., Kikuchi Y. Yeast Ull1/Siz1 is a novel SUMO1/Smt3 ligase for septin components and functions as an adaptor between conjugating enzyme and substrates. J. Biol. Chem. 276:2001;48973-48977.
48. Hagglund R., Van S.C., Lopez P., Roizman B. Herpes simplex virus 1-infected cell protein 0 contains two E3 ubiquitin ligase sites specific for different E2 ubiquitin-conjugating enzymes. Proc. Natl. Acad. Sci. U.S.A. 99:2002;631-636.
49. Pichler A., Gast A., Seeler J.S., Dejean A., Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell. 108:2002;109-120.
50. Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J., Chen Z.J. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 412:2001;346-351.
51. Brown K.D., Hostager B.S., Bishop G.A. Regulation of TRAF2 signaling by self-induced degradation. J. Biol. Chem. 277:2002;19433-19438.
52. Li X., Yang Y., Ashwell J.D. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature. 416:2002;345-347.
53. Hashizume R., Fukuda M., Maeda I., Nishikawa H., Oyake D., Yabuki Y.et al. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 276:2001;14537-14540.
54. Chen A, Kleiman FE, Manley JL, Ouchi T, Pan ZQ. Auto-ubiquitination of the BRCA1/BARD1 RING ubiquitin ligase. J Biol Chem, in press.
55. Tanimura S., Ohtsuka S., Mitsui K., Shirouzu K., Yoshimura A., Ohtsubo M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 447:1999;5-9.
56. Sharp D.A., Kratowicz S.A., Sank M.J., George D.L. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX Protein. J. Biol. Chem. 274:1999;38189-38196.
57. Jackson M.W., Berberich S.J. MdmX protects p53 from Mdm2-mediated degradation. Mol. Cell Biol. 20:2000;1001-1007.
58. Dang J., Kuo M.L., Eischen C.M., Stepanova L., Sherr C.J., Roussel M.F. The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res. 62:2002;1222-1230.
59. Rankin C.A., Joazeiro C.A., Floor E., Hunter T. E3 ubiquitin-protein ligase activity of Parkin is dependent on cooperative interaction of RING finger (TRIAD) elements. J. Biomed. Sci. 8:2001;421-429.
60. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 108:2002;171-182.
61. Ruffner H., Joazeiro C.A., Hemmati D., Hunter T., Verma I.M. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc. Natl. Acad. Sci. U.S.A. 98:2001;5134-5139.
62. Baer R., Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr. Opin. Genet. Dev. 12:2002;86-91.
63. Taniguchi T., Dandrea A.D. Molecular pathogenesis of Fanconi anemia. Int. J. Hematol. 75:2002;123-128.
64. Timmers C., Taniguchi T., Hejna J., Reifsteck C., Lucas L., Bruun D.et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol. Cell. 7:2001;241-248.
65. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M.S., Timmers C., Hejna J.et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell. 7:2001;249-262.
66. Meza J.E., Brzovic P.S., King M.C., Klevit R.E. Mapping the functional domains of BRCA1. Interaction of the RING finger domains of BRCA1 and BARD1. J. Biol. Chem. 274:1999;5659-5665.
67. Li S., Ku C.Y., Farmer A.A., Cong Y.S., Chen C.F., Lee W.H. Identification of a novel cytoplasmic protein that specifically binds to nuclear localization signal motifs. J. Biol. Chem. 273:1998;6183-6189.
68. Jensen D.E., Proctor M., Marquis S.T., Gardner H.P., Ha S.I., Chodosh L.A.et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 16:1998;1097-1112.
69. Fabbro M., Rodriguez J.A., Baer R., Henderson B.R. BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export. J. Biol. Chem. 277:2002;21315-21324.
70. Silletti S., Paku S., Raz A. Tumor cell motility and metastasis: autocrine motility factor as an example of ecto/exoenzyme cytokines. Pathol. Oncol. Res. 3:1997;230-254.
71. Nabi I.R., Watanabe H., Raz A. Autocrine motility factor and its receptor: role in cell locomotion and metastasis. Cancer Metastasis Rev. 11:1992;5-20.
72. Timar J., Trikha M., Szekeres K., Bazaz R., Tovari J., Silletti S.et al. Autocrine motility factor signals integrin-mediated metastatic melanoma cell adhesion and invasion. Cancer Res. 56:1996;1902-1908.
73. Yoon D.Y., Buchler P., Saarikoski S.T., Hines O.J., Reber H.A., Hankinson O. Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 288:2001;882-886.
74. Funasaka T., Haga A., Raz A., Nagase H. Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility. Biochem. Biophys. Res. Commun. 285:2001;118-128.
75. Fang S., Ferrone M., Yang C., Jensen J.P., Tiwari S., Weissman A.M. The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc. Natl. Acad. Sci. U.S.A. 98:2001;14422-14427.
76. Plemper R.K., Wolf D.H. Retrograde protein translocation: ERADication of secretory proteins in health and disease. Trends Biochem. Sci. 24:1999;266-270.
77. Bonifacino J.S., Weissman A.M. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu. Rev. Cell Dev. Biol. 14:1998;19-57.
78. Tiwari S., Weissman A.M. Endoplasmic reticulum (ER)-associated degradation of T cell receptor subunits. involvement of ER-associated ubiquitin-conjugating enzymes (E2s). J. Biol. Chem. 276:2001;16193-16200.
79. Sommer T., Jentsch S. A protein translocation defect linked to ubiquitin conjugation at the endoplasmic reticulum. Nature. 365:1993;176-179.
80. Biederer T., Volkwein C., Sommer T. Role of Cue1p in ubiquitination and degradation at the ER surface. Science. 278:1997;1806-1809.
81. Wilhovsky S., Gardner R., Hampton R. HRD gene dependence of endoplasmic reticulum-associated degradation. Mol. Biol. Cell. 11:2000;1697-1708.
82. Bays N.W., Gardner R.G., Seelig L.P., Joazeiro C.A., Hampton R.Y. Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation. Nat. Cell Biol. 3:2001;24-29.
83. Deak P.M., Wolf D.H. Membrane topology and function of Der3/Hrd1p as a ubiquitin-protein ligase (E3) involved in endoplasmic reticulum degradation. J. Biol. Chem. 276:2001;10663-10669.
84. Yang M., Omura S., Bonifacino J.S., Weissman A.M. Novel aspects of degradation of T cell receptor subunits from the endoplasmic reticulum (ER) in T cells: importance of oligosaccharide processing ubiquitination and proteasome-dependent removal from ER membranes. J. Exp. Med. 187:1998;835-846.
85. Ponting C.P. Proteins of the endoplasmic-reticulum-associated degradation pathway: domain detection and function prediction. Biochem. J. 351(Pt 2):2000;527-535.
86. Zheng N., Wang P., Jeffrey P.D., Pavletich N.P. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell. 102:2000;533-539.
87. Cook W.J., Martin P.D., Edwards B.F., Yamazaki R.K., Chau V. Crystal structure of a class I ubiquitin conjugating enzyme (Ubc7) from Saccharomyces cerevisiae at 2.9 angstroms resolution. Biochemistry. 36:1997;1621-1627.
88. Otto T., Birchmeier W., Schmidt U., Hinke A., Schipper J., Rubben H.et al. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res. 54:1994;3120-3123.
89. Otto T., Bex A., Schmidt U., Raz A., Rubben H. Improved prognosis assessment for patients with bladder carcinoma. Am. J. Pathol. 150:1997;1919-1923.
90. Simard D., Nabi I.R. Inverse relation of autocrine motility factor receptor and E-cadherin expression following MDCK epithelial cell transformation. Biochem. Biophys. Res. Commun. 219:1996;122-127.
91. Benlimame N., Le P.U., Nabi I.R. Localization of autocrine motility factor receptor to caveolae and clathrin-independent internalization of its ligand to smooth endoplasmic reticulum. Mol. Biol. Cell. 9:1998;1773-1786.
92. Le P.U., Guay G., Altschuler Y., Nabi I.R. Caveolin-1 is a negative regulator of caveolae-mediated endocytosis to the endoplasmic reticulum. J. Biol. Chem. 277:2002;3371-3379.
93. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin. Oncol. 28:2001;613-619.
94. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T.et al. NF-κB as a therapeutic target in multiple myeloma. J. Biol. Chem. 277:2002;16639-16647.
95. Shah S.A., Potter M.W., McDade T.P., Ricciardi R., Perugini R.A., Elliott P.J.et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. 82:2001;110-122.
96. Sunwoo J.B., Chen Z., Dong G., Yeh N., Crowl B.C., Sausville E.et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7:2001;1419-1428.
97. Drexler H.C., Risau W., Konerding M.A. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J. 14:2000;65-77.
98. Centner T., Yano J., Kimura E., McElhinny A.S., Pelin K., Witt C.C.et al. Identification of muscle specific RING finger proteins as potential regulators of the titin kinase domain. J. Mol. Biol. 306:2001;717-726.
99. Bodine S.C., Latres E., Baumhueter S., Lai V.K., Nunez L., Clarke B.A.et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294:2001;1704-1708.
100. Gomes M.D., Lecker S.H., Jagoe R.T., Navon A., Goldberg A.L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci U.S.A. 98:2001;14440-14445.
101. Willems A.R., Goh T., Taylor L., Chernushevich I., Shevchenko A., Tyers M. SCF ubiquitin protein ligases and phosphorylation-dependent proteolysis. Philos. Trans. R. Soc. London, B. Biol. Sci. 354:1999;1533-1550.
102. Jackson P.K., Eldridge A.G., Freed E., Furstenthal L., Hsu J.Y., Kaiser B.K.et al. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol. 10:2000;429-439.
103. Tyers M., Jorgensen P. Proteolysis and the cell cycle: with this RING I do thee destroy. Curr. Opin. Genet. Dev. 10:2000;54-64.
104. Hershko D., Bornstein G., Ben-Izhak O., Carrano A., Pagano M., Krausz M.M.et al. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer. 91:2001;1745-1751.
105. Gstaiger M., Jordan R., Lim M., Catzavelos C., Mestan J., Slingerland J.et al. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl. Acad. Sci. USA. 98:2001;5043-5048.
106. Kudo Y., Kitajima S., Sato S., Miyauchi M., Ogawa I., Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res. 61:2001;7044-7047.
107. Harper J.W. Protein destruction: adapting roles for Cks proteins. Curr. Biol. 11:2001;R431-R435.
108. Chiarle R., Fan Y., Piva R., Boggino H., Skolnik J., Novero D.et al. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am. J. Pathol. 160:2002;1457-1466.
109. Ciechanover A., Schwartz A.L. Ubiquitin-mediated degradation of cellular proteins in health and disease. Hepatology. 35:2002;3-6.
110. Ashcroft M., Vousden K.H. Regulation of p53 stability. Oncogene. 18:1999;7637-7643.
111. Freedman D.A., Wu L., Levine A.J. Functions of the MDM2 oncoprotein. Cell Mol. Life Sci. 55:1999;96-107.
112. Chen L., Lu W., Agrawal S., Zhou W., Zhang R., Chen J. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol. Med. 5:1999;21-34.
113. Wang H., Zeng X., Oliver P., Le L.P., Chen J., Chen L.et al. MDM2 oncogene as a target for cancer therapy: an antisense approach. Int. J. Oncol. 15:1999;653-660.
114. Wurl P., Bartel F., Meye A., Kappler M., Bache M., Schmidt H.et al. Growth reduction of a xenotransplanted human soft tissue sarcoma by MDM2 antisense therapy via implanted osmotic minipumps. Int. J. Oncol. 20:2002;1087-1093.
115. Bottger V., Bottger A., Howard S.F., Picksley S.M., Chene P., Garcia-Echeverria C.et al. Identification of novel mdm2 binding peptides by phage display. Oncogene. 13:1996;2141-2147.
116. Bottger A., Bottger V., Sparks A., Liu W.L., Howard S.F., Lane D.P. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7:1997;860-869.
117. Scheffner M., Huibregtse J.M., Howley P.M. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc. Natl. Acad. Sci. U.S.A. 91:1994;8797-8801.
118. Scheffner M. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol. Ther. 78:1998;129-139.
119. Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., Conaway J.W. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10430-10435.
120. 2 sensing. Science. 292:2001;464-468.
121. Levkowitz G., Waterman H., Ettenberg S.A., Katz M., Tsygankov A.Y., Alroy I.et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell. 4:1999;1029-1040.
122. Waterman H., Levkowitz G., Alroy I., Yarden Y. The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J. Biol. Chem. 274:1999;22151-22154.
123. Chen Z.J., Niles E.G., Pickart C.M. Isolation of a cDNA encoding a mammalian multiubiquitinating enzyme (E225K) and overexpression of the functional enzyme in Escherichia coli. J. Biol. Chem. 266:1991;15698-15704.